The Center for Advanced Genetic Screens
Cellecta is a contract research organization whose primary focus is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.
With 7 years of experience performing HT RNAi and peptide screens and 10 NIH grants for genetic screen technology development, Cellecta is at the forefront of the HT genetic screening revolution.
> Learn more about our contract research services or customized products
Validated Pooled Lentiviral shRNA Libraries New
Cellecta, partnered with Agilent Technologies, the Roswell Park Cancer Institute, FHCRC, TSRI, and Illumina, has created one of the most advanced, effective, and reliable pooled shRNA library platforms available.
High-Throughput RNAi Screens with Pooled shRNA Libraries
We'll perform any or all steps, from RNAi screening to HT sequencing to data analysis. Cellecta specializes in negative screens (i.e. viability, apoptosis).
Custom Lentiviral shRNA Constructs New
Validated or Non-validated custom shRNA constructs can be generated using either your vector or Cellecta's, with your choice of tet-regulation, antibiotic resistance, fluorescent marker, and promoters.
2010 Brochure
Download the company brochure for an overview of Cellecta's HT Genetic Screen services.
Recent News
Cellecta receives an NIH SBIR Phase I Grant award (1R43CA144511-01) for the "Isolation of Peptide Radioprotectors". (NIH grant)
Upcoming Events
President and CEO Alex Chenchik will give a talk at the Clark Center, S-363, at Stanford University, Tuesday, August 3rd, from 4-5 pm, announcing a new Genetic Screen Platform and the Discovery of Drug Targets in Cancer Cell Models. (presentation)